What are the different types of liposarcomas, and how do they differ?
here are several different types of liposarcoma, and these types of liposarcoma represent a very broad range of clinical activity. You could begin at one end of the spectrum with a typical lipomatous tumor, also called a well differentiated liposarcoma. These are indolent tumors. They’re not metastatic. They may grow in size, in fact, in maybe a millimeter or so a year. So these are very slow growing. On imaging by CT scan or MRI, these would have the appearance of pretty similar to normal fat, normal fatty tissue. When a surgeon resects a well differentiated or atypical lipomatous tumor, they look very similar to normal fatty tissue.
However, there are more aggressive types of liposarcoma. A well differentiated liposarcoma or an ALT may result in evolution into a dedifferentiated liposarcoma. A dedifferentiated liposarcoma is a more aggressive tumor. These can recur locally. These even can metastasize. These are the types of sarcoma, when metastatic, that we treat with chemotherapy even in the advanced setting. These are sarcomas that could be treated with systemic therapy.
An additional type of liposarcoma is called mixoid or round cell liposarcoma. This type of liposarcoma is different than a dedifferentiated liposarcoma. Dedifferentiated liposarcoma is driven by gene amplification of a chromosome that includes mdm2 and CDK. Mixoid round cell liposarcoma has a different type of translocation that still results in an aggressive tumor with metastatic potential. So those are the basic types of liposarcoma.
The fourth type of liposarcoma would be termed a pleomorphic liposarcoma. This is an aggressive high-grade sarcoma with a high metastatic potential similar to dedifferentiated and mixoid round cell.
CASE: Soft-Tissue Sarcoma Case 2
Michael C is a 59-year-old social worker from Los Angeles California; his medical history is notable for obesity, COPD, and mild hypertension.
In September of 2014, Michael returns for follow up and his CT scan shows a 4 cm posterior mediastinal mass, and a 6 cm perinephric mass suspicious for metastatic disease. He initiates treatment with anthracycline and ifosfamide chemotherapy (6 cycles) for recurrent disease and shows a partial response.
FDA Clears SeCore CDx as Companion Diagnostic for Afami-cel in Synovial Sarcoma
August 7th 2024The FDA has granted 510(k) clearance to the SeCore™ CDx HLA A sequencing system as companion diagnostic for afamitresgene autoleucel in synovial sarcoma, paving the way for a first-of-its-kind solid tumor therapy.
Read More